199 related articles for article (PubMed ID: 32843040)
1. Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs.
Béguin J; Nourtier V; Gantzer M; Cochin S; Foloppe J; Balloul JM; Laloy E; Tierny D; Klonjkowski B; Quemeneur E; Maurey C; Erbs P
BMC Vet Res; 2020 Aug; 16(1):307. PubMed ID: 32843040
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer.
Béguin J; Foloppe J; Maurey C; Laloy E; Hortelano J; Nourtier V; Pichon C; Cochin S; Cordier P; Huet H; Quemeneur E; Klonjkowski B; Erbs P
Mol Ther Oncolytics; 2020 Dec; 19():57-66. PubMed ID: 33072863
[TBL] [Abstract][Full Text] [Related]
3. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.
Béguin J; Gantzer M; Farine I; Foloppe J; Klonjkowski B; Maurey C; Quéméneur É; Erbs P
Sci Rep; 2021 Jan; 11(1):2209. PubMed ID: 33500518
[TBL] [Abstract][Full Text] [Related]
4. The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism.
Foloppe J; Kempf J; Futin N; Kintz J; Cordier P; Pichon C; Findeli A; Vorburger F; Quemeneur E; Erbs P
Mol Ther Oncolytics; 2019 Sep; 14():1-14. PubMed ID: 31011628
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors.
Béguin J; Laloy E; Cochin S; Gantzer M; Farine I; Pichon C; Moreau B; Foloppe J; Balloul JM; Machon C; Guitton J; Tierny D; Klonjkowski B; Quéméneur E; Maurey C; Erbs P
Mol Ther Oncolytics; 2023 Sep; 30():103-116. PubMed ID: 37635744
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.
Autio K; Knuuttila A; Kipar A; Ahonen M; Parviainen S; Diaconu I; Kanerva A; Hakonen T; Vähä-Koskela M; Hemminki A
Vet Comp Oncol; 2016 Dec; 14(4):395-408. PubMed ID: 25302859
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.
Heinrich B; Klein J; Delic M; Goepfert K; Engel V; Geberzahn L; Lusky M; Erbs P; Preville X; Moehler M
Onco Targets Ther; 2017; 10():2389-2401. PubMed ID: 28496337
[TBL] [Abstract][Full Text] [Related]
8. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
[TBL] [Abstract][Full Text] [Related]
9. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent.
Gentschev I; Stritzker J; Hofmann E; Weibel S; Yu YA; Chen N; Zhang Q; Bullerdiek J; Nolte I; Szalay AA
Cancer Gene Ther; 2009 Apr; 16(4):320-8. PubMed ID: 18949014
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
11. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ
Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832
[TBL] [Abstract][Full Text] [Related]
12. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas.
Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA
Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment.
Fend L; Remy-Ziller C; Foloppe J; Kempf J; Cochin S; Barraud L; Accart N; Erbs P; Fournel S; Préville X
Oncoimmunology; 2016 Feb; 5(2):e1080414. PubMed ID: 27057460
[TBL] [Abstract][Full Text] [Related]
14. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy.
Gentschev I; Patil SS; Adelfinger M; Weibel S; Geissinger U; Frentzen A; Chen NG; Yu YA; Zhang Q; Ogilvie G; Szalay AA
Bioengineered; 2013; 4(2):84-9. PubMed ID: 23093804
[TBL] [Abstract][Full Text] [Related]
15. Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.
Cecil A; Gentschev I; Adelfinger M; Nolte I; Dandekar T; Szalay AA
Bioengineered; 2014; 5(5):319-25. PubMed ID: 25482233
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic properties of non-vaccinia poxviruses.
Ricordel M; Foloppe J; Pichon C; Findeli A; Tosch C; Cordier P; Cochin S; Quémeneur E; Camus-Bouclainville C; Bertagnoli S; Erbs P
Oncotarget; 2018 Nov; 9(89):35891-35906. PubMed ID: 30542506
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.
Adelfinger M; Bessler S; Frentzen A; Cecil A; Langbein-Laugwitz J; Gentschev I; Szalay AA
Viruses; 2015 Jul; 7(7):4075-92. PubMed ID: 26205404
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
19. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
Chintala NK; Choe JK; McGee E; Bellis R; Saini JK; Banerjee S; Moreira AL; Zauderer MG; Adusumilli PS; Rusch VW
Front Immunol; 2023; 14():1112960. PubMed ID: 36875061
[TBL] [Abstract][Full Text] [Related]
20. Deletion of
Potts KG; Irwin CR; Favis NA; Pink DB; Vincent KM; Lewis JD; Moore RB; Hitt MM; Evans DH
EMBO Mol Med; 2017 May; 9(5):638-654. PubMed ID: 28289079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
